laboratorios eli lilly and company

What laboratorios eli lilly and company does

Eli Lilly and Company is a global pharmaceutical company founded in 1876 in Indianapolis, United States, and listed on the New York Stock Exchange under ticker LLY. The Spanish subsidiary, LILLY, S.A.U. (branded as Lilly España), operates from Alcobendas, Madrid, and houses one of eight worldwide preclinical R&D centers operated by the parent, along with a manufacturing plant that is currently slated for expansion. The company develops and markets innovative prescription medicines across five core therapeutic areas: diabetes, oncology, immunology, obesity, and neurology, supported by proprietary drug formulations, injection pens, and medical-device administration systems.

The business model is the traditional pharmaceutical model: revenue is generated through the sale of patented prescription medicines distributed via retail pharmacies and hospital procurement channels. Go-to-market relies on field-based medical representatives engaging healthcare professionals, dedicated medical information services, and pharmacovigilance infrastructure, with pricing subject to reimbursement negotiations with Spain's regional Consejerías de Sanidad. Recent product and corporate activity in 2026 includes the launch of Orforglipron (an oral GLP-1 obesity treatment) and the acquisition of AtaiBeckley to expand into treatment-resistant depression and mental health therapies.

The company is governed by a single publicly traded parent with no PE/VC ownership, dispersed institutional shareholders, and a wholly-owned Spanish operating subsidiary. Customer relationships are routed through healthcare professionals, patient populations, and regional health authorities rather than direct enterprise contracts, and the firm actively builds external innovation ecosystems through programs such as Emprende inHealth (11th edition in 2026) and partnerships with Spanish medical societies and patient associations across obesity, endocrinology, and Alzheimer's disease.

Name

laboratorios eli lilly and company

Legal name

Eli Lilly and Company

Website

https://lilly.es

Company type

Public

Founded year

1876

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Eli Lilly and Company is a global pharmaceutical firm founded in 1876 that develops and markets prescription medicines across diabetes, oncology, immunology, obesity, and neurology. Its Spanish subsidiary, Lilly España, operates an R&D center, a manufacturing plant in Alcobendas, and field-based commercial and medical information operations serving healthcare professionals and public health authorities.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Prescription pharmaceuticals
• Biopharmaceutical research
• Diabetes medications
• Oncology therapeutics
• Obesity treatments

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Eli Lilly generates revenue through the sale of innovative prescription medicines across therapeutic areas including diabetes, oncology, immunology, obesity, and neurology. Products are distributed through pharmacies and hospital channels.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Eli Lilly and Company develops, manufactures, and markets innovative prescription medicines across therapeutic areas including diabetes, oncology, immunology, obesity, and neurology. Operations include a global R&D network with eight preclinical research centers, vertically integrated manufacturing facilities, and proprietary injection pen and drug delivery devices. The Spanish subsidiary (LILLY, S.A.U.) operates an R&D center and production plant in Alcobendas, Madrid.

Product overview

Lilly is a global pharmaceutical company that manufactures and markets innovative medications across multiple therapeutic areas. The product portfolio includes prescription medications for diabetes, cancer, immunology, obesity, and neurology. The company also produces injection pens and medical devices for drug administration, supported by dedicated medical information portals. Recent product launches include Orforglipron (oral obesity treatment) and the acquisition of AtaiBeckley for mental health therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Diabetes Medications Prescription medications for the treatment of diabetes, forming one of Lilly's core therapeutic portfolios.
• Oncology Medications Cancer treatments including breast cancer medications and lymphoma therapies.
• Immunology Medications Immunology treatments for psoriatic arthritis, rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, and inflammatory bowel disease.
• Obesity Treatment (Orforglipron) Oral GLP-1 treatment for obesity that can be taken without food or water restrictions, associated with significant weight loss in clinical results.
• Neurology Medications Neurological treatments including Alzheimer's disease diagnostic initiatives and therapies for central nervous system disorders.
• Injection Pens and Devices Proprietary insulin pens and injection devices for administering Lilly medications, supported by a dedicated medical information portal at lillymedical.es for device usage questions.

Quantifiable outcome

• Orforglipron treatment associated with significant weight loss in women across all stages of menopause

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AtaiBeckleycoreStrategic or Co-development Partner · 16 July 2026Lilly acquired AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions, expanding its neuroscience pipeline.
• Emprende inHealth Program (11th Edition)coreStrategic or Co-development PartnerLilly collaborates with health-tech startups through the Emprende inHealth program, now in its 11th edition. Six startups were selected to develop technologies for disease prevention, early diagnosis, and biomedical research improvement.
• Fundación WeberminorStrategic or Co-development PartnerCollaboration with Fundación Weber to produce a report analyzing the social costs of overweight and obesity in Spain, with support from medical societies and patient associations.
• Confederación Española de Asociaciones de Familiares y personas con Alzheimer (CEAFA)minorStrategic or Co-development PartnerPartnership with CEAFA on the Alzheimer's diagnosis journey initiative, highlighting the importance of early diagnosis through patient stories.
• Unlimited (Emprende inHealth)coreGTM or Marketing PartnerCollaboration with Unlimited on the Emprende inHealth startup acceleration program, supporting innovative health technology entrepreneurs.
• Asociación Nacional de Personas que viven con Obesidad (ANPO)minorStrategic or Co-development PartnerPatient association providing endorsement for the Social Value of Better Obesity Control report.
• Sociedad Española de Endocrinología y Nutrición (SEEN)minorStrategic or Co-development PartnerMedical society providing endorsement for the Social Value of Better Obesity Control report.
• Sociedad Española para el Estudio de la Obesidad (SEEDO)minorStrategic or Co-development PartnerMedical society providing endorsement for the Social Value of Better Obesity Control report.
• Sociedad Española de Medicina General (SEMERGEN)minorStrategic or Co-development PartnerMedical society providing endorsement for the Social Value of Better Obesity Control report.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Novo Nordisk: Danish global pharmaceutical company and the dominant incumbent in diabetes and obesity therapeutics with Ozempic and Wegovy. Directly comparable to Eli Lilly as the primary rival in the GLP-1 franchise and broader cardiometabolic specialty space.

Broad incumbents

• Pfizer: One of the world's largest diversified pharmaceutical companies with broad therapeutic area coverage including oncology, vaccines, and inflammation. Direct overlap with Lilly in oncology and immunology, and a competitor pursuing oral GLP-1 and obesity programs.
• Roche: Swiss multinational pharmaceutical and diagnostics company with strong oncology, immunology, and neuroscience portfolios. Directly comparable as a research-driven innovator with overlapping therapeutic areas in oncology and immunology.
• Novartis: Swiss global pharmaceutical company with diversified specialty pharma portfolio across oncology, immunology, cardiovascular, and neurology. Comparable to Lilly as a multi-therapeutic innovator with similar R&D intensity and European operational footprint.
• Merck & Co. U.S.-based multinational pharmaceutical company with leading oncology (Keytruda) and vaccine franchises. Comparable to Lilly as a major branded innovator with significant oncology overlap and similar large-cap pharma dynamics.
• AstraZeneca: British-Swedish multinational with strong oncology, cardiovascular, renal, and respiratory portfolios. Comparable as a research-intensive innovator with overlapping oncology and cardiometabolic interests and major European R&D presence.
• Sanofi: French global pharmaceutical company with specialty care focus including immunology (Dupixent), rare diseases, and vaccines. Comparable as a European-headquartered branded innovator with strong immunology franchise overlap with Lilly.
• Bristol-Myers Squibb: U.S. global pharmaceutical company with leading oncology and immunology portfolios. Comparable as a branded specialty pharma innovator with overlapping oncology and immunology therapeutic areas and similar M&A-driven growth strategy.
• Johnson & Johnson (Innovative Medicine): Diversified healthcare giant with major pharmaceutical division (Janssen) covering oncology, immunology, and neuroscience. Comparable as a large-cap innovator with overlapping immunology and oncology franchises, plus growing neuroscience footprint.
• GlaxoSmithKline (GSK): British global pharmaceutical company with specialty medicines, vaccines, and HIV franchises. Comparable as a European-headquartered branded innovator with overlap in respiratory and immunology, and similar operating model across multiple therapeutic areas.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eli-lilly-and-company

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about laboratorios eli lilly and company